(NYSEMKT: TOVX) Theriva Biologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.92%.
Theriva Biologics's earnings in 2025 is -$26,190,000.On average, 4 Wall Street analysts forecast TOVX's earnings for 2025 to be -$189,967,686, with the lowest TOVX earnings forecast at -$182,517,973, and the highest TOVX earnings forecast at -$195,554,971. On average, 4 Wall Street analysts forecast TOVX's earnings for 2026 to be -$112,363,133, with the lowest TOVX earnings forecast at -$191,114,834, and the highest TOVX earnings forecast at -$26,569,969.
In 2027, TOVX is forecast to generate -$99,629,792 in earnings, with the lowest earnings forecast at -$158,380,632 and the highest earnings forecast at -$35,426,625.